Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurent Greillier

Showing results (121-130 of 153) with videos related to

Pageof 16
Sort By:
Frontiers in Oncology|May 8, 2026
Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumorsAntoine Italiano, Teresa García Manrique, Enrique Grande Pulido, et al.
Journal for Immunotherapy of Cancer|August 23, 2024
Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort studyLambert Assoumou, Raghiatou Baldé, Christine Katlama, et al.
Lung Cancer (Amsterdam, Netherlands)|May 24, 2022
Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcomeAlice Mogenet, Fabrice Barlesi, Benjamin Besse, et al.
Clinical Lung Cancer|March 23, 2025
First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing ≥ 50% PD-L1 (ESCKEYP GFPC 05-2018)Romain Corre, Chantal Decroisette, Jean-Bernard Auliac, et al.
Lancet (London, England)|January 1, 2016
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trialGérard Zalcman, Julien Mazieres, Jacques Margery, et al.
Lancet (London, England)|January 24, 2021
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trialPaul Baas, Arnaud Scherpereel, Anna K Nowak, et al.
The Lancet. Oncology|September 4, 2025
Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trialJordi Remon, Paolo Bironzo, Nicolas Girard, et al.
Trials|April 14, 2017
PREDOMOS study, impact of a social intervention program for socially isolated elderly cancer patients: study protocol for a randomized controlled trialElodie Crétel-Durand, Emilie Nouguerède, Hervé Le Caer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2019
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 TrialJean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette, et al.
European Journal of Cancer (Oxford, England : 1990)|December 29, 2021
Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC networkArthur Petat, Eric Dansin, Fabien Calcagno, et al.
Pageof 16

Showing results (121-130 of 153) with videos related to

Sort By:
Pageof 16
Frontiers in Oncology|May 8, 2026
Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumorsAntoine Italiano, Teresa García Manrique, Enrique Grande Pulido, et al.
Journal for Immunotherapy of Cancer|August 23, 2024
Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort studyLambert Assoumou, Raghiatou Baldé, Christine Katlama, et al.
Lung Cancer (Amsterdam, Netherlands)|May 24, 2022
Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcomeAlice Mogenet, Fabrice Barlesi, Benjamin Besse, et al.
Clinical Lung Cancer|March 23, 2025
First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing ≥ 50% PD-L1 (ESCKEYP GFPC 05-2018)Romain Corre, Chantal Decroisette, Jean-Bernard Auliac, et al.
Lancet (London, England)|January 1, 2016
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trialGérard Zalcman, Julien Mazieres, Jacques Margery, et al.
Lancet (London, England)|January 24, 2021
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trialPaul Baas, Arnaud Scherpereel, Anna K Nowak, et al.
The Lancet. Oncology|September 4, 2025
Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trialJordi Remon, Paolo Bironzo, Nicolas Girard, et al.
Trials|April 14, 2017
PREDOMOS study, impact of a social intervention program for socially isolated elderly cancer patients: study protocol for a randomized controlled trialElodie Crétel-Durand, Emilie Nouguerède, Hervé Le Caer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2019
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 TrialJean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette, et al.
European Journal of Cancer (Oxford, England : 1990)|December 29, 2021
Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC networkArthur Petat, Eric Dansin, Fabien Calcagno, et al.
Pageof 16